Procept Biorobotics Corp is expected to report Q3 2026 revenue of $100.52 million and a loss per share of $0.39, with its current stock price of $20.16 trading slightly below the average analyst target of $22.25.
The primary focus for investors this quarter is the commercial traction and procedure volume of the newly launched HYDROS Robotic System, which features AI-powered surgical technology for BPH treatment.
Analysts are closely monitoring whether the HYDROS platform rollout can drive sustained market share gains and accelerate the company's path toward profitability. Recent clinical expansion and new research initiatives in prostate cancer are also expected to be key discussion points during the management call.